Yang X, Liu C, Lei Y, Liu Z, Zhu B, Zhao D
Front Immunol. 2024; 15:1443784.
PMID: 39372407
PMC: 11449710.
DOI: 10.3389/fimmu.2024.1443784.
Baek H, Kim N, Park J, Kwon T, Kim S
Inflamm Res. 2024; 73(10):1671-1685.
PMID: 39079978
PMC: 11457682.
DOI: 10.1007/s00011-024-01924-2.
Meur S, Mukherjee S, Roy S, Karati D
Mol Neurobiol. 2024; 61(12):10941-10955.
PMID: 38816674
DOI: 10.1007/s12035-024-04257-7.
Ko R, Seo J, Park H, Lee N, Lee S
Exp Mol Med. 2022; 54(11):2092-2103.
PMID: 36446848
PMC: 9722908.
DOI: 10.1038/s12276-022-00893-y.
Cacheiro-Llaguno C, Hernandez-Subira E, Diaz-Munoz M, Fresno M, Serrador J, Iniguez M
Int J Mol Sci. 2022; 23(21).
PMID: 36362060
PMC: 9653600.
DOI: 10.3390/ijms232113275.
Arc Regulates Transcription of Genes for Plasticity, Excitability and Alzheimer's Disease.
Leung H, Foo G, VanDongen A
Biomedicines. 2022; 10(8).
PMID: 36009494
PMC: 9405677.
DOI: 10.3390/biomedicines10081946.
Transcriptional analysis of lung fibroblasts identifies PIM1 signaling as a driver of aging-associated persistent fibrosis.
Pham T, Lee J, Guan J, Caporarello N, Meridew J, Jones D
JCI Insight. 2022; 7(6).
PMID: 35167499
PMC: 8986080.
DOI: 10.1172/jci.insight.153672.
A systematic review on active sites and functions of PIM-1 protein.
Zhao Y, Aziz A, Zhang H, Zhang Z, Li N, Liu B
Hum Cell. 2022; 35(2):427-440.
PMID: 35000143
DOI: 10.1007/s13577-021-00656-3.
DYRK1A activates NFATC1 to increase glioblastoma migration.
Liu H, Sun Q, Chen S, Chen L, Jia W, Zhao J
Cancer Med. 2021; 10(18):6416-6427.
PMID: 34309232
PMC: 8446559.
DOI: 10.1002/cam4.4159.
Pim1 Kinase Inhibitors Exert Anti-Cancer Activity Against HER2-Positive Breast Cancer Cells Through Downregulation of HER2.
Wang B, Huang C, Liu L, Cheng F, Wei Y, Lin Y
Front Pharmacol. 2021; 12:614673.
PMID: 34267653
PMC: 8276059.
DOI: 10.3389/fphar.2021.614673.
PIM kinases inhibit AMPK activation and promote tumorigenicity by phosphorylating LKB1.
Mung K, Eccleshall W, Santio N, Rivero-Muller A, Koskinen P
Cell Commun Signal. 2021; 19(1):68.
PMID: 34193159
PMC: 8247201.
DOI: 10.1186/s12964-021-00749-4.
DGG-100629 inhibits lung cancer growth by suppressing the NFATc1/DDIAS/STAT3 pathway.
Im J, Kim B, Yoon S, Cho B, Baek Y, Kang M
Exp Mol Med. 2021; 53(4):643-653.
PMID: 33859351
PMC: 8102629.
DOI: 10.1038/s12276-021-00601-2.
The role of Pim kinase in immunomodulation.
Liu Z, Han M, Ding K, Fu R
Am J Cancer Res. 2021; 10(12):4085-4097.
PMID: 33414987
PMC: 7783746.
PIM1 accelerates prostate cancer cell motility by phosphorylating actin capping proteins.
Santio N, Vainio V, Hoikkala T, Mung K, Lang M, Vahakoski R
Cell Commun Signal. 2020; 18(1):121.
PMID: 32771000
PMC: 7414696.
DOI: 10.1186/s12964-020-00618-6.
Phosphorylation of NFATC1 at PIM1 target sites is essential for its ability to promote prostate cancer cell migration and invasion.
Eerola S, Santio N, Rinne S, Kouvonen P, Corthals G, Scaravilli M
Cell Commun Signal. 2019; 17(1):148.
PMID: 31730483
PMC: 6858710.
DOI: 10.1186/s12964-019-0463-y.
PIM-Related Kinases Selectively Regulate Olfactory Sensations in .
Kalichamy K, Ikkala K, Porsti J, Santio N, Tuomaala J, Jha S
eNeuro. 2019; 6(4).
PMID: 31387876
PMC: 6709224.
DOI: 10.1523/ENEURO.0003-19.2019.
Loss of PIM1 correlates with progression and prognosis of salivary adenoid cystic carcinoma (SACC).
Xu J, Zhu X, Li Q, Chen C, Guo Z, Tan Z
Cancer Cell Int. 2018; 18:22.
PMID: 29467592
PMC: 5819291.
DOI: 10.1186/s12935-018-0518-y.
evaluation of dihydropyridine-3-carbonitriles as potential cytotoxic agents through PIM-1 protein kinase inhibition.
Abnous K, Manavi H, Mehri S, Alibolandi M, Kamali H, Ghandadi M
Res Pharm Sci. 2017; 12(3):196-203.
PMID: 28626477
PMC: 5465828.
DOI: 10.4103/1735-5362.207200.
Identification of Novel Nuclear Factor of Activated T Cell (NFAT)-associated Proteins in T Cells.
Gabriel C, Gross F, Karl M, Stephanowitz H, Hennig A, Weber M
J Biol Chem. 2016; 291(46):24172-24187.
PMID: 27637333
PMC: 5104941.
DOI: 10.1074/jbc.M116.739326.
Phosphorylation of Notch1 by Pim kinases promotes oncogenic signaling in breast and prostate cancer cells.
Santio N, Landor S, Vahtera L, Yla-Pelto J, Paloniemi E, Imanishi S
Oncotarget. 2016; 7(28):43220-43238.
PMID: 27281612
PMC: 5190019.
DOI: 10.18632/oncotarget.9215.